|
(MoneyNewsWire.Net, November 03, 2017 ) According to the report Europe Biosimilars Market, published by Market Data Forecast, the market is projected to reach USD 7.37 billion by 2021, at a CAGR of 33.0% from 2016 to 2021.
Today, nearly 8 in 10 prescriptions filled in the Europe are for Generic Drugs. The use of Biosimilars Industry is expected to grow over the next few years as a number of popular drugs come off patent through 2015. FDA requires Biosimilars to have the same quality and performance as brand name drugs. Research shows that generics work just as well as brand name drugs.
Biosimilars are made from living cells that have the capability to treat diseases using recombinant DNA technology and controlled gene expression. Most of the biosimilars are made from bacteria, viruses, plants and animals. Biosimilar drugs are used in prevention and cure of various diseases such as rheumatoid arthritis, cancer, chronic kidney failure, oncology, diabetes, heart attacks, autoimmune diseases, growth hormone deficiency, and infectious disease.
Get a comprehensive overview of the Biosimilars Market: http://www.marketdataforecast.com/market-reports/europe-biosimilars-market-1144/
Europe Biosimilars Market: Drivers & Restraints
The growth of Biosimilars Market is driven by competitive edge over branded drugs due to cost-effectiveness. Limited healthcare resources across many European countries result in underutilization of important biosimilars for conditions such as cancer and rheumatoid arthritis, largely due to their cost and a lack of proper support from state-run programs. These factors contribute to below optimal adoption of clinical practice recommendations and poor care across the region.
Factors restraining the growth of market are strict regulations set up by FDA, high manufacturing costs and the alternatives of lower priced generic drugs.
Get accurate market forecast and analysis on the Europe Biosimilars Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/europe-biosimilars-market-1144/request-sample
Europe Biosimilars Market: Segmentation
By Product Type
Protein
Insulin
Human Growth Hormones
Granulocyte Colony-stimulating Factor (G-CSF)
Interferons
Recombinant Glycosylated Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
By Applications
Chronic Diseases
Autoimmune Diseases
Blood disorders
Oncology disease
Growth Hormone Deficiency
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/europe-biosimilars-market-1144/customize-report
Europe Biosimilars Market: Overview
Biosimilars have accounted for large percentage in the European Pharmaceutical expenditure but relatively lower amount of prescriptions. Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars. Oncology segment is expected to grow at a higher CAGR due to rising prevalence of cancer cases. Biosimilars for conditions such as breast cancer, rheumatoid arthritis and non-small cell lung cancer are presently being developed and may soon be out in the market.
Europe Biosimilars Market: Region-wise Outlook
Based on Regional Analysis, this region is further categorized in to UK, Spain, Germany, France, and others. Europe dominates the biosimilar market. In the coming years, several new classes of biosimilars are expected to be submitted for approval in Europe. Most existing drugs are expected to lose their EU patents by 2020, including leading treatments for breast cancer, diabetes and rheumatoid arthritis. Overall, the opportunities in biosimilar research are expected to escalate throughout Europe.
Key Questions Answered
What is the current and future Biosimilars Market outlook in Europe? What trends are affecting the market?
What is the competitive landscape and market share of major players in the Biosimilars Market space in Europe?
What are the key, high growth markets that Biosimilars Market manufacturers should expand into? Which market segments are growing the fastest?
What are the unmet needs with the Biosimilars currently on the market? How will emerging technologies fulfil these unmet needs?
What is patient perception and market outlook of Biosimilars?
What are the challenges and barriers that have hindered widespread adoption of Biosimilars?
Europe Biosimilars Market: Key Players
Some of the major companies dominating the market, by their products include Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddys Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics and Cipla Ltd.
Reasons to buy Europe Biosimilars Market Report:
Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Europe Pharmaceuticals Segment:
Europe Anti-Fungal Drugs Market: http://www.marketdataforecast.com/market-reports/latin-america-anti-fungal-drugs-market-248/
Europe Weight Loss and Diet Management Market: http://www.marketdataforecast.com/market-reports/latin-america-weight-loss-and-diet-management-market-1744/
Europe Psoriasis Drugs Market: http://www.marketdataforecast.com/market-reports/latin-america-psoriasis-drugs-market-1722/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options.
For more information, kindly visit, www.marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
|
